Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 221 for:    umbilical cord mesenchymal stem cells

The Safety/Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy for Lumbar Discogenic Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04104412
Recruitment Status : Recruiting
First Posted : September 26, 2019
Last Update Posted : September 26, 2019
Sponsor:
Information provided by (Responsible Party):
Sclnow Biotechnology Co., Ltd.

Brief Summary:

This experimental use umbilical cord mesenchymal stem cells in treatment of the early stage of lumbar discogenic pain (endogenous pain of the disc) to evaluate its safety and efficacy.

This experimental is mainly aimed at over 18years old people, regardless of gender, with refractory and persistent back pain for more than 6 months.

The efficacy and safety of mesenchymal stem cells (MSCS) were evaluated by low-temperature plasma ablation and intravertebral disc injection, which were divided into treatment group and control group.


Condition or disease Intervention/treatment Phase
Lumbar Discogenic Pain Biological: human umbilical cord mesenchymal stem cell Phase 1

Detailed Description:

This experimental use umbilical cord mesenchymal stem cells in treatment of the early stage of lumbar discogenic pain (endogenous pain of the disc) to evaluate its safety and efficacy.

This experimental is mainly aimed at over 18years old people, regardless of gender, with refractory and persistent back pain for more than 6 months.

The straight leg elevation test was 70 degrees negative. Magnetic Resonance Imaging (MRI) of the lumbar spine showed herniated disc < 6 mm, no obvious compression of spinal cord and nerve roots. T2-weighted mri of the lumbar spine showed decreased single/multisegment signal in the intervertebral disc (black disc sign) or High intensity zone (HIZ) in the posterior part of the intervertebral disc annulus. The clinical signs of nerve localization were consistent with MRI changes.

The efficacy and safety of mesenchymal stem cells (MSCS) were evaluated by low-temperature plasma ablation and intravertebral disc injection, which were divided into treatment group and control group.

The safety evaluation including:physical examination, vital signs, routine hematuria and faeces, liver and kidney function, blood lipids, electrolytes, coagulation, rapid virus detection, tumor markers, electrocardiogram and adverse reaction records at the 3, 6, 12 and 24 weeks before and after treatment.

The prime efficacy evaluation is VAS( visual analogue scale) at the 3, 6, 12 and 24 weeks before and after treatment.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 242 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Safety/Efficacy Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Lumbar Discogenic Pain
Actual Study Start Date : August 15, 2019
Estimated Primary Completion Date : February 1, 2020
Estimated Study Completion Date : July 31, 2024

Arm Intervention/treatment
Experimental: treatment group A (with mesenchymal stem cell intervention)
observe the effectiveness and safety of patients by injecting human umbilical cord mesenchymal stem cells(2*10^7/ml normal saline) and Low temperature plasma vaporization ablation
Biological: human umbilical cord mesenchymal stem cell
2*10^7

No Intervention: control group B
observe the effectiveness and safety of patients by injecting normal saline and Low temperature plasma vaporization ablation



Primary Outcome Measures :
  1. Validity evaluation by detection the change of the VAS pain score relief rate for Lumbar disc pain of participants in different time point and compare with the VAS pain score before treatment [ Time Frame: 24 weeks ]

    Recording the VAS scores at 3, 6, 12 and 24 weeks after the operation and compare with the VAS score before the operation.

    Pain relief rate =(VAS before treatment - VAS after treatment)/VAS before treatment ×100%.

    VAS scale Use a line with 10 centimeters long as a point between 1 and 10

    0 points, no pain, no pain sensation;

    1-3 points, mild pain, no effect

    4-6 points, moderate pain, affecting work but not life;

    7-10 points, severe pain, severe pain, affect work and life.

    Efficacy evaluation: more than 75% is the basic remission; 50%-75% is effective; 25%-50% effective; Less than 25% is invalid.

    e.g. the VAS score before the operation is 8, the score in the third week after operation is 6, the pain relief rate is (8-6)/8x 100%=14.3% the VAS score before the operation is 8, the score in the sixth week after operation is 3, the pain relief rate is (8-3)/8x 100%=62.5%



Secondary Outcome Measures :
  1. Observe treatment [ Time Frame: 24weeks ]

    Secondary measures were assessed at 3, 6, 12 and 24 weeks before and after treatment, including:

    Subjective indicators:

    ODI(The Oswestry Disability Index) score:

    0%-20%: Minimal disability: This group can cope with most living activities. Don't need treatment.

    20%-40% Moderate disability: This group experiences more pain and problems with sitting, lifting, and standing. Personal care, sexual activity, and sleeping are not grossly affected, and the back condition can usually be managed by conservative means.

    40%-60%: Severe disability: Pain remains the main problem in this group of patients, but travel, personal care, social life, sexual activity, and sleep are also affected.

    60%-80%: Crippled: Back pain impinges on all aspects of these patients' lives—both at home and at work—and positive intervention is required.

    80%-100%: These patients are either bed-bound or exaggerating their symptoms. Need evaluated by careful observation of the patient during medical examination.


  2. Safety evaluation by detecting adverse events and serious adverse events [ Time Frame: 24 weeks ]
    Observe for any adverse reactions, including fever, pain, or bleeding to evaluate the changes of safety indexes at the 3、6、12、24weeks after treatment.

  3. Safety evaluation by detecting Activated partial thromboplastin time (APTT) [ Time Frame: 24 weeks ]

    Being the Activated partial thromboplastin time (APTT) test for the patients to examine the changes of safety indexes at the 3、6、12、24 weeks after treatment.

    time of 25-37 seconds. Abnormalities over 10 seconds should be compared with normal controls.


  4. Safety evaluation by detecting Prothrombin time (PT) [ Time Frame: 24 weeks ]

    Being the Prothrombin time (PT) test for the patients to examine the changes of safety indexes at the 3、6、12、24 weeks after treatment.

    time of 11-14 seconds. Abnormalities over 3 seconds in comparison with normal controls are required. Activity: 80-120% INR: 0.8-1.2


  5. Safety evaluation by detecting Fibrinogen [ Time Frame: 24 weeks ]

    Fibrinogen test for the patients to examine the changes of safety indexes at the 3、6、12、24 weeks after treatment.

    The Fibrinogen should in 2-4g/L


  6. Safety evaluation by detecting Thrombin time (TT) [ Time Frame: 24 weeks ]

    Thrombin time (TT) test for the patients to examine the changes of safety indexes at the 3、6、12、24 weeks after treatment.

    the time of 12-16 seconds, TT need to be abnormal for more than 3 seconds compared with normal controls




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. age over 18
  2. refractory and persistent lumbago pain for more than 6 months, with/without radiation pain in lower limbs, and poor conservative treatment effect;
  3. the straight leg elevation test was 70 degrees negative;
  4. MRI of lumbar spine showed herniated disc < 6 mm, no obvious compression of spinal cord and nerve roots; T2-weighted mri of the lumbar spine showed decreased single/multi-segment signal (black disc sign) or High signal zone (HIZ) in the posterior part of the intervertebral disc annulus.
  5. clinical signs of nerve localization were consistent with MRI changes;
  6. subject gives informed consent and signs informed consent.

Exclusion Criteria:

  1. coagulation dysfunction or anticoagulant therapy;
  2. intervertebral space infection, puncture site infection or systemic infection;
  3. lumbago pain of non-spinal origin, such as sacroiliac joint origin pain;
  4. patients who have had open surgery or other disc treatments;
  5. imaging examination suggested disc prolapse, prolapse, spinal canal bone stenosis, etc.;
  6. patients with vital organ system dysfunction and tumor lumbar vertebra metastasis;
  7. subjects with high tumor markers (AFP/CEA/CA199/CA125);
  8. the subject is pregnant or breastfeeding;
  9. subjects also receive other treatments that may affect the efficacy and safety of stem cells;
  10. failing to control alcohol and other substance abuse during the 6 months prior to enrollment and enrollment period;
  11. the subjects suffer from mental illness, or lack of understanding, communication and cooperation, and cannot be guaranteed to follow the study protocol;

Subjects who are not willing to sign informed consent and are participating in other clinical trials or have participated in other clinical trials within 3 months;


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04104412


Contacts
Layout table for location contacts
Contact: Jiaxiang Ni, Master 8613910743476 nijiaxiang@yahoo.com
Contact: Lei Guo, Doctor 861064368977 georgeguo@sclnow.com

Locations
Layout table for location information
China, Beijing
Xuanwu Hospital Capital Medical University Recruiting
Beijing, Beijing, China, 100053
Contact: Jiaxiang Ni, Master    13901743476    nijiaxiang@yahoo.com   
Contact: Yuanzhang Tang, Doctor         
Sponsors and Collaborators
Sclnow Biotechnology Co., Ltd.
Investigators
Layout table for investigator information
Study Director: Yuanzhang Tang, Doctor Xuanwu Hospital, Beijing

Layout table for additonal information
Responsible Party: Sclnow Biotechnology Co., Ltd.
ClinicalTrials.gov Identifier: NCT04104412     History of Changes
Other Study ID Numbers: SCLnow-XW-01
First Posted: September 26, 2019    Key Record Dates
Last Update Posted: September 26, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sclnow Biotechnology Co., Ltd.:
lumbar discogenic pain
mesenchymal stem cell